For example, separate testing for the BRAF c.1799T>A variant (p.V600E), following FLA or IHC, is recommended to increase the specificity of LS screening (Newland et al., 2017), but both MSI and BRAF can be analyzed by a single tumor sequencing assay (Hampel et al., 2018). The gene discussed is BRAF; the disease is neoplasm.